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Summary
Background Introduction of human papillomavirus (HPV) vaccination has been slow in low-income and middle-
income countries (LMICs) because of resource constraints and worldwide shortage of vaccine supplies. To help 
inform WHO recommendations, we modelled various HPV vaccination strategies to examine the optimal use of 
limited vaccine supplies and best allocation of scarce resources in LMICs in the context of the WHO global call to 
eliminate cervical cancer as a public health problem.
Methods In this mathematical modelling analysis, we developed HPV-ADVISE LMIC, a transmission-dynamic model 
of HPV infection and diseases calibrated to four LMICs: India, Vietnam, Uganda, and Nigeria. For different 
vaccination strategies that encompassed use of a nine-valent vaccine (or a two-valent or four-valent vaccine assuming 
high cross-protection), we estimated three outcomes: reduction in the age-standardised rate of cervical cancer, 
number of doses needed to prevent one case of cervical cancer (NNV; as a measure of efficiency), and the incremental 
cost-effectiveness ratio (ICER; in 2017 international $ per disability-adjusted life-year [DALY] averted). We examined 
different vaccination strategies by varying the ages of routine HPV vaccination and number of age cohorts vaccinated, 
the population targeted, and the number of doses used. In our base case, we assumed 100% lifetime protection 
against HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52, and HPV-58; vaccination coverage of 80%; and a time 
horizon of 100 years. For the cost-effectiveness analysis, we used a 3% discount rate. Elimination of cervical cancer 
was defined as an age-standardised incidence of less than four cases per 100 000 woman-years.
Findings We predicted that HPV vaccination could lead to cervical cancer elimination in Vietnam, India, and Nigeria, 
but not in Uganda. Compared with no vaccination, strategies that involved vaccinating girls aged 9–14 years with 
two doses were predicted to be the most efficient and cost-effective in all four LMICs. NNV ranged from 78 to 381 and 
ICER ranged from $28 per DALY averted to $1406 per DALY averted depending on the country. The most efficient 
and cost-effective strategies were routine vaccination of girls aged 14 years, with or without a later switch to routine 
vaccination of girls aged 9 years, and routine vaccination of girls aged 9 years with a 5-year extended interval between 
doses and a catch-up programme at age 14 years. Vaccinating boys (aged 9–14 years) or women aged 18 years or older 
resulted in substantially higher NNVs and ICERs.
Interpretation We identified two strategies that could maximise efforts to prevent cervical cancer in LMICs given 
constraints on vaccine supplies and costs and that would allow a maximum of LMICs to introduce HPV vaccination.
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Introduction
Globally, in 2020, an estimated 604 000 new cases of 
cervical cancer and 342 000 cervical cancer-related deaths 
occurred.1 Over 80% of cases of cervical cancer occur in 
low-income and middle-income countries (LMICs).1 
These inequalities in the burden of cervical cancer are set 
to increase, with 88% of high-income countries (HICs) 
having introduced HPV vaccination in women and girls 
as of the end of 2019 compared with less than 
40% of LMICs.1–3 Furthermore, as of the end of 2019, 44% 
of high-income countries also vaccinate boys, compared 
with only 5% of LMICs.3 The reasons for the lower 
uptake of HPV vaccination in LMICs, which have 
been exacerbated by the COVID-19 pandemic, include 
financial and human resource constraints,4 paucity of 
evidence on its population-level effectiveness and cost-
effectiveness in LMICs,5 and, importantly, worldwide 
shortage of HPV vaccine supply.6
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Because of the substantial burden and inequalities in 
the distribution of cervical cancer across the world, the 
WHO Director-General Tedros Adhanom Ghebreyesus 
made a global call for action towards the elimination of 
cervical cancer as a public health problem.7 This initiative 
would entail efforts to achieve high coverage of routine 
vaccination in girls, but could also include efforts to 
accelerate elimination by vaccinating multiple age cohorts 
of women, introducing gender-neutral vaccination (ie, 
vaccination of both boys and girls), and increasing uptake 
of cervical cancer screening. In the context of the call for 
elimination of cervical cancer and limited resources, 
HPV vaccination policy decisions in LMICs will probably 
require trade-offs between two potentially conflicting 
perspectives: maxi mising population-level impact (eg, to 
reach elimination of cervical cancer) versus optimising 
vaccination efficiency and return on investment (eg, to 
minimise the number of doses needed to prevent one 
case of cancer and to minimise the cost-effectiveness 
ratio).
The main HPV vaccination policy questions being 
examined in LMICs by their health authorities and by 
WHO are as follows: what are the ages and the number 
of age cohorts that should be vaccinated? Should only 
girls or girls and boys be vaccinated? And how many and 
when should doses be given per vaccinee?6 To date, 
results from modelling studies have predicted that 
routine and multiple-age cohort HPV vaccination of girls 
is likely to be highly cost-effective in most LMICs.8,9 
However, most models for LMICs have not included 
realistic country-specific representation of sexual 
behaviour and natural history of HPV infection and 
cervical cancer and have not been designed to examine 
other, more complex policy questions (eg, adding 
vaccination of boys and different strategies among girls 
aged 9–14 years). Moreover, to our knowledge, no 
comprehensive modelling analysis has investigated the 
optimal HPV vaccination strategies in terms of efficiency 
and return on investment for any part of the world while 
simultaneously comparing different ages at vaccination, 
multiple age-cohort vaccination strategies, girls-only 
versus gender-neutral vaccination, and the interval 
between doses.
In this Article, we present the modelling results that 
were presented to the WHO Strategic Advisory Group of 
Experts on Immunization (SAGE) in October, 2019, to help 
inform their global HPV vaccination policy recom-
mendations.10 The objective of the modelling study was to 
identify optimal HPV vaccination strategies in the context 
of elimination of cervical cancer, vaccine shortage, and 
resource constraints. We used a transmission-dynamic 
mathematical model to estimate the population-level 
effect, efficiency, and cost-effectiveness of 27 HPV vacci-
nation strategies varying the age of routine vaccination 
(9 years or 14 years), number of age cohorts vaccinated, the 
population targeted (girls only or girls and boys), and the 
interval between doses.
Methods
Study design and countries
In this mathematical modelling analysis, we modelled 
the impact of HPV vaccination in four countries: 
India, Vietnam, Uganda, and Nigeria. We selected 
these countries because of differences between their 
Research in context
Evidence before this study
Approximately 500 000 new cases of cervical cancer are 
diagnosed in low-income and middle-income countries 
(LMICs) each year. Human papillomavirus (HPV) vaccines are 
highly effective: the Papillomavirus Rapid Interface for 
Modelling and Economics (PRIME) model predicted that HPV 
vaccination of girls aged 12 years with two doses of the vaccine 
was cost-effective in 156 (87%) of 179 countries. However, 
less than 40% of LMICs have introduced HPV vaccination 
programmes. Key barriers to introduction include financial and 
human resource constraints, and, since 2019, a worldwide 
shortage of HPV vaccine supply that might last until 2024. 
These barriers might have been intensified by the COVID-19 
pandemic. In parallel, the WHO director-general has 
issued a global call to eliminate cervical cancer as a public 
health problem, which will result in sustained efforts to 
achieve high vaccination coverage across LMICs.
Added value of this study
In this modelling analysis we identified two novel 
HPV vaccination strategies that should minimise the number 
of doses needed to prevent one case of cervical cancer and the 
cost per DALY averted: two-dose routine vaccination of girls 
aged 14 years with or without a later switch to routine 
vaccination of girls aged 9 years, and routine vaccination of 
girls aged 9 years with an extended interval of 5 years between 
doses and a catch-up programme for girls aged 14 years. 
These strategies would maximise prevention of cervical 
cancer with the fewest doses in the short term and at the 
lowest cost, which would allow a maximum of LMICs to 
introduce HPV vaccination and could reduce the effect of 
HPV vaccine supply shortage on efforts to eliminate cervical 
cancer.
Implication of all the available evidence
Our modelling results have directly informed WHO Strategic 
Advisory Group of Experts on Immunization’s recommendation 
in October, 2019, to continue vaccination with a two-dose 
schedule; temporarily postpone vaccination of multiple-age 
cohorts, older age groups (≥15 years), and gender-neutral 
vaccination; and consider implementing strategies such as 
those identified in our study.
Articles
1600 www.thelancet.com/infection   Vol 21   November 2021
See Online for appendix 3
For technical appendix see 
https://marc-brisson.net/
HPVadvise-LMIC.pdf
For Demographic Health Survey 
Data see https://dhasprogram.
com
See Online for appendix 4
populations in sexual behaviour, HPV prevalence, and 
cervical cancer burden. For example, according to 
Demographic Health Survey data, the mean number of 
lifetime sexual partners for men was 1·4 in Vietnam, 
1·9 in India, 4·1 in Nigeria, and 6·6 in Uganda; the 
estimated HPV prevalence in a 2010 meta-analaysis11 was 
less than 10% in south (India) and southeast (Vietnam) 
Asia compared with more than 20% in sub-Saharan Africa 
(Nigeria and Uganda); and the age-standardised 
incidence of cervical cancer in 2020 was estimated 
to be less than 20 cases per 100 000 woman-years 
in Vietnam and India compared with more than 
30 per 100 000 woman-years in Nigeria and Uganda.12 
Furthermore, sufficient data were available to calibrate 
and validate the models to these countries (data sources 
are in appendix 3 [p 8] and online).
Vaccination scenarios
For the four countries, we first compared seven HPV 
vaccination scenarios with two doses, starting with routine 
vaccination of girls aged 9 years. We then added the 
vaccination of multiple-aged cohorts of girls and women 
aged 9–14 years, 9–18 years, or 9–25 years within the first 
year of the programme. Finally, we added the vaccination 
of boys aged 9–14 years to the previous multiple-aged 
cohort vaccination scenarios of girls and women 
(appendix 4 p 2). Because of the shortage of HPV 
vaccines4,13 and the WHO recommendation to vaccinate 
girls aged 9–14 years,14 we then examined seven strategies 
that could potentially optimise two-dose vaccination of 
girls aged 9–14 years (appendix 4 [pp 2, 25–26]). These 
strategies involved increasing the interval between doses 
(from the currently recommended 6-month interval to 
5 years), delaying the age of routine vaccination to 
14 years (with or without a subsequent switch to routine 
vaccination at age 9 years), implementing catch-up 
campaigns for the first 5 years of the programme, and 
various other combinations (appendix 4 p 2). In sensitivity 
analysis, we examined the same multiple-aged cohort 
vaccination scenarios (9–14 years, 9–18, years, 9–25 years) 
for girls only or girls and boys, but giving only one dose to 
girls and boys aged 9–14 years. These vaccination strategies 
were developed in collaboration with the WHO HPV 
Working Group to ensure they were relevant for SAGE 
recommendations. In our base case, we assumed 80% 
vaccination coverage.
Model structure
To examine HPV vaccination policy questions in 
LMIC settings we developed HPV-ADVISE LMIC, an 
individual-based, transmission-dynamic model of 
multiple types of HPV infection and disease 
(appendix 3 pp 1–5). HPV-ADVISE LMIC has the same 
underlying structure for all LMICs and the same basic 
model structure as previous versions of HPV-ADVISE 
for HICs,15,16 with modifications to capture differences 
in sexual behaviour between LMICs and HICs and 
to examine elimination of cervical cancer. The 
main difference between HPV-ADVISE LMIC and 
HPV-ADVISE for HICs is that we included female sex 
workers and their clients in HPV-ADVISE LMIC because 
the proportion of men who declare they have paid for sex 
is higher in some LMICs than in HICs,17 male clients of 
female sex workers have been shown to be bridge 
populations for sexually transmitted infections,18,19 and 
female sex workers, as a core group for HPV transmission, 
might have a role in whether elimination of cervical 
cancer can be achieved.20
In HPV-ADVISE LMIC, individuals are attributed one 
of four mutually exclusive levels of sexual activity: level 0, 
including women and men who are married and remain 
married to a single partner throughout their life; level 1, 
including women who get married and then divorce or 
whose partner has a concurrent partner during their 
marriage (excluding female sex workers) and men who 
get married and then divorce or have a concurrent 
partnership during their marriage (excluding female sex 
workers); level 2, including women and men who never 
get married; and level 3, including female sex workers 
and men who pay for sex. Notably, men who pay for 
sex can also have concurrent long-term partnerships 
with level 0–1 women. These definitions of levels of 
sexual activity were chosen because they are good 
markers of sexual behaviour and risk of HPV infection in 
these countries, and valid data sources are available 
(appendix 3 p 21). The model includes stable (long-term) 
and casual partnerships. Partnership formation and 
dissolution are based on age-specific, gender-specific, 
and sexual activity-specific rates of partner acquisition 
and separation and mixing patterns. HPV transmission 
depends on sexual behaviour, per sex act probability 
of transmission, and natural history of infection 
(determined by the duration of infectiousness and 
natural immunity). 18 HPV types, including all types in 
the nine-valent vaccine, were modelled individually and 
independently (assuming no synergy or competition). 
Each HPV type has its own natural history parameters 
in terms of transmission, persistence, clearance, and 
disease progression to cervical cancer. After clearance, 
individuals might develop type-specific natural 
immunity. The natural history of cervical cancer is repre-
sented by the following type-specific health states: 
susceptible to HPV infection; infected; immune; cervical 
intraepithelial neoplasia of grade 1 (CIN1), grade 2 
(CIN2), and grade 3 (CIN3); and three stages of cervical 
cancer.
Model parameters
We parametrised and calibrated the model to each 
country separately. We estimated the parameter values 
determining sexual behaviour, HPV transmission, and 
the natural history of HPV infection and cervical cancer 
by calibrating the model to country-specific data 
(appendix 3 pp 6–51). For each country, we identified 
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50 parameter sets that simultaneously fit highly 
stratified country-specific sexual behaviour and HPV 
epidemiological data (appendix 4 pp 27–31), taken from 
published articles, specific studies, and international 
population-based datasets (appendix 3 p 8). These 
50 parameter sets represent uncertainty in model 
parameters and variability in sexual behaviour and 
HPV epidemiology within a country. Additionally, we 
validated the model to verify whether the model fit 
data that were not used during model calibration 
(appendix 3 pp 52–56).
We obtained age-specific and country-specific mortality 
rates from the WHO Global Health Observatory data 
repository21 and country-specific screening parameters 
from the Institut Català d’Oncologia Information Centre 
on HPV and Cancer.22–25 Notably, most women (aged 
≥18 years) from India, Vietnam, Uganda, and Nigeria 
have never been screened for cervical cancer (91–100% of 
women).22–25
We assumed that the HPV vaccines were prophylactic 
and do not affect the natural history of HPV infection or 
disease among individuals infected by a vaccine type 
before vaccination. In the model, vaccine efficacy is 
specific to each of the 18 HPV types modelled. In our 
base case, we assumed that two doses of HPV vaccine 
provide 100% efficacy against infection with HPV-16, 
HPV-18, HPV-31, HPV-33, HPV-45, HPV-52, and 
HPV-58 (representing either a nine-valent vaccine or a 
two-valent or four-valent vaccine with very high cross-
protection) and that duration of protection is lifelong. 
In sensitivity analyses, we investigated one-dose 
vaccination strategies, in which we assumed that one 
dose of vaccine could provide an efficacy against 
infection of 95% or 85% with a duration of protection of 
30 or 20 years. We also varied vaccine efficacy against 
cross-protective types for the two-valent and four-valent 
vaccines (high26 or none).
We used two different vaccine prices per dose: 
$4·60 per dose (based on Gavi, the Vaccine Alliance prices) 
and $7·50 per dose (1·5 × Gavi price) in 2017 international 
$ (INT$). The vaccine delivery and operational costs 
were country specific and based on estimates from 
the Papillomavirus Rapid Interface for Modelling and 
Economics (PRIME) model.8 Treatment costs for cervical 
cancer were based on HPV pilot studies and from analyses 
using WHO-CHOICE methodologies.27,28 Costs were 
inflated to 2017 INT$ (INT$1 would buy in the cited 
country a similar amount of goods and services US$1 
would buy in the USA;29 appendix 4 p 4).
Outcomes
We had three main outcomes (appendix 4 p 24). First, to 
examine the potential for elimination of cervical cancer, 
we used the absolute reduction of the age-standardised 
incidence of cervical cancer over time as our 
main population-level impact outcome. We used 
age-standardised incidence below four cases per 
100 000 woman-years as the threshold for elimination of 
cervical cancer because this is the working definition 
used by WHO.30 Our secondary population-level impact 
outcomes were the relative reduction in age-standardised 
incidence of cervical cancer and prevalence of HPV-16 
and HPV-18 (appendix 4 pp 6–7). Second, to examine the 
optimal use of limited vaccine supplies, we used the 
number of doses needed to prevent one case of cervical 
cancer (NNV) as our efficiency outcome. Finally, to 
examine optimal return on investment we used an 
incremental cost-effectiveness analysis. Our main 
cost-effectiveness outcome was the incremental cost-
effectiveness ratio (ICER) in costs per disability-adjusted 
life-year (DALY) averted.
Analysis
For age-standardisation of the incidence of cervical 
cancer, we used the age structure of the 2015 world 
female population aged 0–99 years.31 We calculated the 
effectiveness of vaccination strategies as the pre-
vaccination incidence minus the incidence at equilibrium 
divided by the pre-vaccination incidence. We estimated 
the NNV by dividing the total number of doses given in a 
population over time by the number of cases of cervical 
cancer prevented over the same period. We calculated 
incremental NNVs as the additional number of doses 
needed to prevent an additional case of cervical cancer. 
For the first step in our cost-effectiveness analysis, we 
incrementally compared different strategies varying the 
number of cohorts, age, and population targeted (ie, we 
gradually increased the number of individuals vaccinated 
by either vaccinating additional cohorts of girls or by 
adding the vaccination of boys; appendix 4 p 2). For the 
second step, to identify optimal vaccination strategies of 
girls aged 9–14 years (appendix 4 pp 2, 25–26), we 
compared all strategies with no vaccination. We 
calculated ICERs as the additional cost per additional 
DALY saved. For reference, we used two country-
specific cost-effectiveness thresholds, represented by the 
countries’ gross domestic product (GDP) per capita and 
0·5 × GDP per capita (India: $7056 and $3528; Vietnam: 
$6776 and $3388; Uganda: $1864 and $932; and Nigeria: 
$5861 and $2930).32 We did the economic analysis from 
the health-care payer perspective, including all direct 
medical costs. We discounted costs and outcomes at 
3% per year following WHO recommendation.
We modelled a 100-year time-horizon to capture both 
short-term and long-term benefits of HPV vaccination 
on the incidence of cervical cancer and associated 
mortality (ie, the time horizon was set at a point in time 
when all countries are at equilibrium, meaning that 
incidence and prevalence measures are constant over 
time).
We present all model predictions with the 10th and 
90th percentiles (80% uncertainty interval) of the 
model predictions taken from the distribution of 
1000 simulation results for each country (50 parameter 
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sets × 20 simulations per parameter set), and the mean of 
the ten parameter sets that provide the best fit (using 
weighted least squares) to the estimated incidence of 
cervical cancer from Globocan 2020.12 The HPV-ADVISE 
LMIC model was implemented in C++ (version 11).
Role of the funding source
WHO contributed to the study design, data collection, 
data analysis, data interpretation, and writing of the 
report. The Canadian Institute of Health Research, Fonds 
de recherche du Québec - Santé, The Bill & Melinda Gates 
Foundation, and Compute Canada had no role in the 
study design, data collection, data analysis, data 
interpretation, or writing of the report.
Results
All described analyses model vaccination with two doses 
of HPV vaccine, unless otherwise indicated. Under base 
case assumptions, we predicted that routine vaccination 
of girls only, with 80% coverage, would lead to substantial 
decreases in the incidence of cervical cancer (figure 1; 
appendix 4 pp 5–7). At equilibrium, routine vaccination 
of girls aged 9 years is predicted to reduce the 
age-standardised incidence per 100 000 woman-
years of cervical cancer from 19 to three cases in India 
(ie, 85% effectiveness), from nine cases to one case 
in Vietnam (ie, 84% effectiveness), from 57 to 12 cases in 
Uganda (79% effectiveness), and from 34 to seven cases 
in Nigeria (79% effectiveness). Routine vaccination of 
girls aged 14 years (figure 1; appendix 4 p 5) would 
accelerate the decrease in incidence compared with 
vaccinating girls aged 9 years because they are closer to 
becoming sexually active and becoming exposed to HPV 
but is expected to produce a slightly lower decrease in 
age-standardised incidence in the long term (figure 1). 
The difference in incidence at equilibrium between 
routine HPV vaccination of girls aged 9 years and those 
aged 14 years is predicted to vary between less than one 
case per 100 000 woman-years in Vietnam (difference in 
effectiveness of <1%) and one case per 100 000 woman-
years in the other LMICs (difference in effectiveness of 
1–4%), due to differences in the proportion of girls who 
are infected before age 14 years.
Our model predicts that routine vaccination of girls 
aged 9 years, with vaccination of girls aged 9–14 years in 
the first year of the programme as part of a multiple-aged 
Figure 1: Predicted population-level impact of two-dose routine vaccination of girls aged 9 years vs aged 14 years in four low-income and 
middle-income countries
Predicted data are the mean of the ten best fit parameter sets to Globocan 2020 estimated incidences of cervical cancer. Numbers to the right of the graphs indicate 
the incidence at equilibrium. Predictions were made under the base case assumptions.
0
0 10 20 30 40 50
Years since start of vaccination programme Years since start of vaccination programme
























































































Routine vaccination of girls aged 9 years








www.thelancet.com/infection   Vol 21   November 2021 1603
cohort vaccination programme combines the advantages 
of the long-term benefit of routine vaccination of girls 
aged 9 years and the faster decreases in incidence that 
were seen with routine vaccination of girls aged 14 years 
(figure 2). Vaccination of additional cohorts of girls or 
young women up to age 18 or 25 years would further 
accelerate decreases in the incidence of cervical cancer 
(figure 2; appendix 4 p 5) and therefore prevent a larger 
cumulative number of cases over time. However, in the 
long term, the strategy of vaccinating multiple older-age 
cohorts has no effect on the incidence of cervical cancer 
or whether elimination can be reached—ie, long-term 
incidence of cervical cancer is only affected by the routine 
strategy that is implemented (figures 1, 2).
Our model predicts very similar population-level 
effectiveness with the different vaccination strategies of 
girls aged 9–14 years (figure 3; appendix 4 pp 2, 25–26). 
The post-vaccination dynamics in age-standardised 
incidence of cervical cancer are predicted to be identical 
for the strategy of routine vaccination of girls aged 9 years 
using the current two-dose interval and that of routine 
vaccination of girls aged 9 years using the extended 
interval (ie, first dose at age 9 years and second dose at 
age 14 years), if the first dose and second dose have the 
same vaccine efficacy or vaccination coverage (figure 3; 
appendix 4 pp 25–26). The dynamics are also very similar 
for the following strategies: routine vaccination of girls 
aged 9 years with vaccination of girls aged 9–14 years in 
the first year of the programme, routine vaccination of 
girls aged 9 years with an extended interval of 5 years 
between doses and a catch-up campaign for girls aged 
14 years, or routine vaccination of girls aged 14 years with 
a later switch to routine vaccination of girls aged 9 years 
(figure 3; appendix 4 pp 25–26).
Vaccinating boys in addition to girls with two doses of 
vaccine both accelerates the decrease in age-standardised 
incidence of cervical cancer and further decreases the 
incidence at equilibrium (figure 4; appendix 4 pp 5–7). 
In the long term, gender-neutral vaccination with 
80% vaccination coverage is predicted to decrease the 
age-standardised incidence per 100 000 woman-years 
of cervical cancer from 19 cases to one case in India 
(ie, 95% effectiveness), from nine cases to fewer 
than one case in Vietnam (96% effectiveness), from 
57 to five cases in Uganda (91% effectiveness), and from 
34 to three cases in Nigeria (90% effectiveness). Finally, 
at 80% vaccination coverage, gender-neutral vaccination 
with vaccination of boys and girls aged 9–14 years in the 
Figure 2: Predicted population-level impact of two-dose routine vaccination of girls aged 9 years, with MAC vaccination in the first year of the programme
Girls older than 14 years are always given three doses. Predicted data are the mean of the ten best fit parameter sets to Globocan 2020 estimated incidences of cervical 
cancer. Numbers to the right of the graphs indicate the incidence at equilibrium. Predictions were made under the base case assumptions. MAC=multiple-age cohort.
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first year of the programme leads to a 90–96% reduction 
in HPV-16 and HPV-18 prevalence (vs 50–87% with girls-
only vaccination with multiple-aged cohort vaccination of 
girls aged 9–14 years; appendix 4 pp 6–7).
Our model predicted that, compared with no 
vaccination, routine vaccination of girls aged 9 years, with 
additional vaccination of girls aged 9–14 years in the first 
year of the programme, was the most efficient and cost-
effective vaccination strategy in all four countries, when 
varying simultaneously the number of cohorts, age of 
cohorts, and population targeted for vaccination. This 
strategy extendedly dominated routine vaccination of 
girls aged 9 years only (ie, was more costly but had lower 
ICER; figure 5; appendix 4 pp 8–9, 17–20). When 
examining the incremental efficiency and cost-
effectiveness of vaccinating more individuals, either by 
increasing the number of age cohorts of girls vaccinated 
in the first year of introducing the vaccination programme 
(aged 15–18 years) or by vaccinating boys aged 9–14 years, 
our model predicted that vaccinating supplementary 
cohorts of girls would be optimal in all countries 
(figure 5). Compared with vaccinating girls aged 
9–14 years, the NNV and incremental cost-effectiveness of 
extending vaccination to girls aged 15–18 years were 
similar (figure 5), and dominated vaccinating boys aged 
9–14 years. Compared with vaccinating girls aged 
9–18 years, vaccinating women up to age 25 years was 
estimated to be more efficient and cost-effective than 
adding vaccination of boys. Finally, strategies that 
involved vaccinating boys were the least efficient and cost-
effective, with NNVs to prevent one case of cancer being 
six to eight times higher than when vaccinating girls and 
women up to age 25 years. However, ICERs remained 
below the GDP per capita threshold for all strategies.
When examining different vaccination strategies of 
girls aged 9–14 years, our model predicted that, compared 
with no vaccination, all vaccination strategies were highly 
efficient and cost-effective and led to very similar 
NNVs and ICERs (figure 6; appendix 4 pp 10–11, 17–20). 
Nonetheless, our model predicted that routine 
vaccination of girls aged 14 years, with or without a later 
switch to routine vaccination of girls aged 9 years, and 
routine vaccination of girls aged 9 years with an extended 
interval between doses and catch-up vaccination at age 
Figure 3: Predicted population-level impact of different two-dose HPV vaccination strategies targeting girls aged 9–14 years
For the extended interval strategy, the first dose is given at age 9 years and the second dose at age 14 years. Predicted data are the mean of the ten best fit 
parameter sets to Globocan 2020 estimated incidences of cervical cancer. Numbers to the right of the graphs indicate the incidence at equilibrium. Predictions were 
made under the base case assumptions. MAC=multiple-age cohort.
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14 years were the most efficient and cost-effective 
strategies.
Sensitivity analysis examining population-level impact, 
the NNV to prevent one case of cancer, and cost-
effectiveness of HPV vaccination strategies for different 
numbers of doses and vaccines used are presented in 
appendix 4 (pp 12–16, 32–35). Compared with no 
vaccination, one-dose vaccination of girls aged 9–14 years 
is highly efficient and cost-effective. When assuming 
one-dose vaccine-type efficacy is greater than 85% and 
duration of protection is lifelong, vaccinating older 
cohorts of girls, women, and boys would be more 
efficient and cost-effective than giving a second 
dose to girls aged 9–14 years in all countries 
(appendix 4 pp 14–16, 34–35). However, if one dose has a 
shorter duration of protection (eg, 20 years), then the 
strategy of giving a second dose to girls aged 9–14 years 
and the strategy of adding the vaccination of older girls 
or women (with three doses for older girls and women) 
would be equally efficient and cost-effective as each other 
(appendix 4 pp 12–13, 34–35).
Compared with no vaccination, our model predicts 
very similar ICERs for the different vaccines (appendix 4 
pp 21–22). Furthermore, the findings of the most efficient 
and cost-effective strategies do not change according to the 
vaccine that is used (data not shown). Finally, if the two-
valent or four-valent vaccines have no cross-protection 
against non-vaccine types, the use of the nine-valent 
vaccine costing $2·90 more than the two-valent or four-
valent vaccine would be cost-effective (ICERs between 
$430 per DALY averted for Uganda and $3875 per DALY 
averted for India; appendix 4 p 22). However, if the two-
valent or four-valent vaccines have high cross-protection, 
ICERs are higher for Vietnam, Uganda, and Nigeria than 
ICERs that assume no cross-protection with the two-valent 
or four-valent vaccines (appendix 4 p 22).
Discussion
Of all HPV vaccination strategies examined with two 
doses, those that involved vaccinating girls aged 9–14 years 
are predicted to be the most efficient and cost-effective in 
the four LMICs examined. Among these strategies, 
routine vaccination of girls aged 14 years with or without a 
later switch to routine vaccination of girls aged 9 years and 
routine vaccination of girls aged 9 years with an extended 
interval of 5 years between doses and a catch-up 
Figure 4: Predicted population-level impact of two-dose routine vaccination of girls vs girls and boys aged 9–14, with MAC vaccination in the first year of the 
programme
Predicted data are the mean of the ten best fit parameter sets to Globocan 2020 estimated incidences of cervical cancer. Numbers to the right of the graphs indicate 
the incidence at equilibrium. Predictions were made under the base case assumptions. MAC=multiple-age cohort.
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programme for girls aged 14 years are predicted to be the 
most efficient and cost-effective strategies. Compared 
with no vaccination, these strategies produce NNVs 
between 78 and 351 and ICERs between $28 per DALY 
averted and $1149 per DALY averted depending on the 
country and vaccine price. Vaccination strategies that 
included boys or older cohorts of women were substantially 
less efficient and cost-effective than vaccination strategies 
that included girls aged 9–18 years only. Finally, 
HPV vaccination of girls only and boys and girls with high 
coverage could lead to elimination of cervical cancer 
(ie, less than four cases per 100 000 woman-years) in 
countries with incidences of cervical cancer between those 
of Vietnam (age-standardised incidence of cervical cancer 
of nine cases per 100 000 woman-years) and Nigeria 
(34 cases per 100 000 woman-years), but not in countries 
Figure 5: Predicted incremental efficiency and cost-effectiveness of different two-dose vaccination strategies varying the number of cohorts, age, and population targeted (girls 
only vs girls and boys)
Strategies in the blue boxes are those that are incrementally more efficient and cost-effective when vaccinating additional cohorts of individuals (ie, the cost-effectiveness frontier). Dotted arrows and 
boxes indicate dominated strategies or extended dominated strategies (ie, strategies that were not the most efficient or cost-effective up the chain). ICERs that are bold are below 0·5 × GDP per capita 
(appendix 4 p 4). ICERs that are purple and italic are above 0·5 × GDP per capita but below GDP per capita. ICER1 is the scenario in which cost per vaccine dose, including administration costs, is 
INT$4·60. ICER2 is the scenario in which cost per vaccine dose, including administration costs, is INT$7·50. Routine vaccination occurs constantly, whereas MAC vaccination occurs in the first year of 
the vaccination programme only. Predictions were made under the base case assumptions. GDP=gross domestic product. ICER=incremental cost-effectiveness ratio per disability-adjusted life-year 
averted. INT$=international dollar for 2017. MAC=multiple age cohort. NNV=number of doses needed to prevent one case of cervical cancer. *The comparator was no vaccination. †The comparator 
was the strategy of routine vaccination of girls aged 9 years and MAC vaccination of girls aged 9–14 years. ‡The comparator was the strategy of routine vaccination of girls aged 9 years and MAC 
vaccination of girls aged 9–18 years. §For MAC vaccination of girls and boys, age of girls and women is as indicated and boys are aged 9–14 years in all instances. ¶The comparator was the strategy of 
routine vaccination of girls aged 9 years and MAC vaccination of girls and women aged 9–25 years.
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with an incidence similar to, or higher than, that of 
Uganda (57 cases per 100 000 woman-years), despite such 
countries potentially achieving substantial reductions in 
the incidence of cervical cancer. In countries like Uganda, 
adding cervical screening to female or gender-neutral 
vaccination will likely be required to reach elimination. 
Indeed, one modelling study suggested that the addition 
of twice lifetime HPV screening at ages 35 years and 
45 years to HPV vaccination is needed for elimination of 
cervical cancer in countries with high incidences.33 WHO 
has created the WHO Global Cervical Cancer Elimination 
Modelling Consortium to identify the most efficient and 
cost-effective combinations of HPV vaccination, cervical 
screening, and treatment likely to lead to elimination.34,35
Our findings have important implications for 
HPV vaccination policy decisions in LMICs in the context 
of limited supplies of vaccine. Our results suggest that the 
most efficient HPV vaccination strategies, as measured by 
NNV, are those that target girls aged 9–14 years. By 
contrast, vaccinating older girls and women or boys is 
much less efficient, with NNVs that are up to ten times 
higher than when vaccinating girls aged 9–14 years. 
Partly based on these results, in October, 2019, SAGE 
recommended that countries should temporarily postpone 
the implementation of gender-neutral vaccination and 
vaccination of girls and women in older age groups 
(≥15 years), at least until HPV vaccine supply shortages 
are resolved.10 Additionally, SAGE recommended that 
multiple-age cohort vaccination of girls aged 9–14 years, 
which requires a large number of doses during the first 
year of the programme, should also be postponed to 
alleviate the demand for vaccine doses in the coming 
years. The WHO recommended alternative strategies are 
variations on the optimal strategies identified in our 
analysis—ie, routine two-dose vaccination of girls aged 
13 or 14 years, with or without a later switch to routine 
vaccination in younger girls (ie, aged 9 or 10 years) and 
routine vaccination at age 9 or 10 years with an extended 
interval of 3–5 years between doses combined with catch-
up programme for girls aged 14 years. Given that the 
recommended vaccination strategies have very similar 
NNVs and ICERs, small changes in vaccination coverage 
or age of sexual debut could lead to changes in the ranking 
of the optimal strategy. Hence, the choice of strategy 
should be country-specific and will need to consider issues 
of programmatic feasibility and acceptability and the 
potential to obtain the greatest vaccination coverage before 
girls become sexually active.
Our results suggest that routine vaccination of girls 
aged 13 or 14 years, with or without a later switch to 
routine vaccination at an earlier age (ie, 9 or 10 years), 
would allow countries to retain the accelerated impact of 
vaccinating multiple-age cohorts while restricting the 
number of doses required in the first years after 
Figure 6: Predicted efficiency and cost-effectiveness of different two-dose HPV vaccination strategies targeting girls aged 9–14 years (all strategies are compared with no vaccination)
Strategies in the blue boxes are those that are incrementally more efficient and cost-effective when vaccinating additional cohorts of girls. Dotted arrows and boxes indicate dominated strategies or 
extended dominated strategies (ie, strategies that were not the most efficient or cost-effective up the chain). All ICERs in this figure are below 0·5 GDP per capita (appendix 4 p 4). ICER1 is the scenario in 
which cost per vaccine dose, including administration costs, is INT$4·60. ICER2 is the scenario in which cost per vaccine dose, including administration costs, is INT$7·50. Routine vaccination occurs 
constantly, whereas MAC vaccination occurs in the first year of the vaccination programme only. Predictions were made under the base case assumptions. GDP=gross domestic product. ICER=incremental 
cost-effectiveness ratio per disability-adjusted life-year averted. INT$=international dollar for 2017. MAC=multiple age cohort. NNV=number of doses needed to prevent one case of cervical cancer. 
*First dose at age 9 years and second dose at age 14 years (assuming the same coverage). †Two doses at age 9 years and a 5-year catch-up at age 14 years. ‡First dose at age 9 years and second 
dose at age 14 years (assuming the same coverage) plus a 5-year catch-up vaccination of girls aged 14 years.
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programme implementation. Compared with routine 
vaccination of girls aged 9 years, routine vaccination of 
girls aged 14 years has two main advantages: it accelerates 
health benefits by targeting girls closer to becoming 
sexually active, and it targets girls just before they age out 
of the 9–14 years age category (these girls would be missed 
with routine vaccination at younger ages). However, the 
population-level effectiveness of routine vaccination of 
girls aged 13 or 14 years (vs routine vaccination of girls 
aged 9 years or multiple-age cohort vaccination of girls 
aged 9–14 years) will depend on the proportion of girls 
who are sexually active before the age of vaccination and 
whether sufficiently high vaccination coverage can be 
achieved. We found that the long-term population-level 
effectiveness of routine vaccination of girls aged 14 years 
would be 3–4% percentage points lower than routine 
vaccination of girls aged 9 years in countries such as 
Nigeria and India, which have a relatively high proportion 
of girls aged 14 years who are sexually active (15–25%).36,37 
Notably, even in countries with a high proportion of girls 
who are sexually active at a relatively young age, the 
difference in estimated population-level effectiveness 
between strategies remains small probably because of 
herd immunity from vaccination (ie, reducing the risk of 
infection among unvaccinated girls who are sexually 
active by reducing the circulation of HPV in this 
population). In countries where school attendance 
substantially decreases with older age, vaccinating girls at 
age 13 years (or the oldest age at which school attendance 
is achieved) rather than at age 14 years could be considered 
to improve coverage. Importantly, routine vaccination of 
girls aged 13 or 14 years with a later switch to routine 
vaccination at age 9 or 10 years would probably be the 
optimal strategy if vaccination coverage is not as high as 
expected or a high proportion of girls are sexually active 
before age 14 years, or both. Such a strategy would allow a 
country to benefit from the short-term advantages of 
vaccinating older girls (accelerated benefits and 
minimising the number of missed vaccine cohorts) and 
long-term benefits of vaccinating younger girls 
(potentially increased coverage and vaccination before 
girls become sexually active).
Routine vaccination of girls aged 9 years with a 5-year 
extended interval between doses combined with a catch-up 
programme for girls aged 14 years was predicted to provide 
the same accelerated benefits and long-term population-
level effectiveness as multiple age-cohort vaccination of 
girls aged 9–14 years in the first year of the programme, 
but with fewer vaccine doses required in the short term 
and lower NNVs and ICERs. An important advantage of 
this extended-interval vaccination strategy is that it offers 
countries the opportunity to not give a second dose if the 
results from single-dose vaccine efficacy randomised 
clinical trials are positive.38 Indeed, post-hoc analysis of 
randomised trials and post-vaccination surveillance studies 
suggest that single-dose HPV vaccination could provide 
protection against HPV infections and related diseases.39 
The vaccine efficacy and duration of protection of one dose 
of HPV vaccine is unknown, but results of randomised 
trials are expected in the next 2–5 years. If a second dose is 
not deemed to be required in the next 5 years, our results 
predict that countries that introduce extended-interval 
dosing programmes will have implemented the most 
efficient and cost-effective vaccination strategy, and 
saved substantial medical costs. However, if two doses of 
HPV vaccine remain necessary, maintaining high 
vaccination coverage for the second dose at age 
13 or 14 years will be important. If the extended-interval 
vaccination strategy also includes catch-up vaccination at 
age 14 years, countries can have time to implement 
programmes to increase vaccination coverage in that age 
group. Additionally, although not included in our model 
assumptions, an extended interval would allow girls who 
missed their first dose at age 9 years to be vaccinated at age 
14 years. Furthermore, little is known about the vaccine 
efficacy of 3–5 year extended-interval schedules, and such 
a strategy would be considered off-label use of the vaccine. 
To our knowledge, the only study that has examined this 
interval found that extended intervals resulted in similar 
levels of geometric mean IgG antibody titres when the 
second dose was given 6 months or 3–8 years after the first 
dose.40 Finally, WHO recommended that countries 
consider routine vaccination of girls aged 9 years with a 
3–5 year extended interval between doses (with a catch-up 
programme at age 14 years) after careful consideration of 
its programmatic challenges, and with a clear and well 
planned communication strategy.10
Our study has five major strengths. First, to our 
knowledge, this is the first comprehensive modelling 
analysis to simultaneously compare HPV vaccination 
strategies with different ages at vaccination, numbers of 
age cohorts targeted, gender targeted, numbers of doses, 
and intervals between doses. Second, our model 
was calibrated to LMIC-specific sexual activity and 
epidemiological data. We selected two Asian and 
two African countries, representing different profiles in 
terms of sexual activity and HPV-related burden, for which 
good-quality data were available for us to calibrate and 
validate our model. Even though these countries are very 
different in terms of number of lifetime partners and 
incidence of cervical cancer, the optimal HPV vaccination 
strategies in terms of efficiency and cost-effectiveness were 
consistent. Hence, our results are probably generalisable 
to most LMICs, except potentially LMICs in the Middle East 
and north Africa, which have a lower incidence of cervical 
cancer than other LMICs. Third, our model predictions are 
based on 50 parameter sets, capturing uncertainty in key 
parameters and within-country variability in sexual activity 
and HPV and cervical cancer epidemiology. Fourth, our 
model predictions, which suggested that all vaccination 
strategies for girls aged 9–14 years we investigated are 
highly efficient and cost-effective, are robust when using a 
different number of doses (one dose vs two dose) or type of 
vaccine (two-valent, four-valent, or nine-valent). Finally, we 
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developed these vaccination strategies for girls aged 
9–14 years in collaboration with the WHO HPV Working 
group to ensure that our modelling results were responsive 
to the needs of policy makers.
Our study also has some limitations. First, although we 
considered seven different vaccination strategies of girls 
aged 9–14 years, we did not model all possible combinations 
of ages at vaccination and vaccination coverage. For this 
reason, our results should be considered as general 
principles guiding HPV vaccination policy decisions in the 
different countries. For example, the most efficient 
strategies are those initially vaccinating the oldest age 
cohort before they became sexually active (through routine 
vaccination or catch-up to accelerate health benefits) and 
long-term routine vaccination at a younger age (to 
maximise coverage and minimise the likelihood of 
vaccinating previously infected girls). Second, our model 
does not account for the effect of HIV, which increases the 
likelihood of acquisition of HPV and disease progression, 
or the effect of HIV treatment, which might attenuate the 
effects of HIV on HPV acquisition and disease progression. 
Hence, the effect of HPV vaccination on the incidence of 
cervical cancer might be overestimated in settings with a 
high prevalence of HIV or might mean that specific 
prevention strategies might be required for people living 
with HIV to enable elimination of cervical cancer. These 
questions are being examined as part of the WHO Cervical 
Cancer Elimination Modeling Consortium.30
In summary, HPV vaccination strategies that target girls 
aged 9–14 years are the most optimal for use of scarce 
resources. In the context of limited supply of HPV vaccines 
and the COVID-19 pandemic, two-dose routine vaccination 
of girls aged 13 or 14 years, with or without a later switch to 
routine vaccination at an earlier age and routine vaccination 
at age 9 or 10 years with an extended interval of 3–5 years 
between doses combined with a programme of catch-up 
vaccination of girls aged 14 years are the strategies that 
would minimise the number of doses required in the short 
term for maximum prevention of cervical cancer. These 
strategies would allow the maximum number of countries 
to introduce HPV vaccination and could reduce the effect 
of vaccine supply shortage on efforts to eliminate cervical 
cancer.
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